目的 探讨宫颈癌组织 SLIT3、SPARCL1 蛋白表达与根治术后复发的关系。方法 选择 2019年10月至2021年4月在医院接受宫颈癌根治术治疗的患者107例作为研究对象，并选择30例子宫良性病变手术切除患者作为对照组；随访 1 年根据随访结果分为复发组（n = 25）和未复发组（n = 82）。实时荧光定量检测（qPCR）组织 SLIT3、SPARCL1 mRNA 表达水平，免疫组化检测 SLIT3、SPARCL1 蛋白表达水平，分析SLIT3、SPARCL1蛋白表达与临床病理特征相关性，COX模型分析影响宫颈癌患者根治术后复发的危险因素。结果 107 例根治术患者中 25 例患者复发，复发率为 23.36%；SLIT3 低表达患者术后复发率 （31.15%）显著高于 SLIT3 高表达患者术后复发率（13.04%），SPARCL1 低表达患者术后复发率（32.31%）显 著高于SPARCL1高表达患者术后复发率（9.52%），差异有统计学意义（P < 0.05）。宫颈癌组SLIT3、SPARCL1 mRNA表达显著低于对照组，差异有统计学意义（P < 0.05）；复发组患者宫颈癌组织SLIT3、SPARCL1 mRNA 水平显著低于未复发患者，差异有统计学意义（P < 0.05）。宫颈癌组织SLIT3、SPARCL1蛋白表达与分化程度、临床分期、淋巴结转移、基质浸润深度相关（P < 0.05），与年龄、病理类型、肿瘤最大径无关（P > 0.05）。 COX 单因素分析显示，分化程度、临床分期、淋巴结转移、基质浸润深度、SLIT3 蛋白表达、SPARCL1 蛋白表达与宫颈癌患者根治术后复发相关（P < 0.05）；COX多因素分析显示，中/高分化、Ⅱa分期、淋巴结转移、基质浸润深度> 50%、SLIT3蛋白低表达、SPARCL1蛋白低表达是影响宫颈癌患者根治术后复发的独立危险因 素（P < 0.05）。结论 宫颈癌组织SLIT3、SPARCL1水平均低于正常宫颈组织，SLIT3、SPARCL1蛋白低表达 是影响宫颈癌根治术后复发的独立危险因素，对预测宫颈癌术后复发具有一定的临床意义。 

Objective To investigate the relationship between the expression of SLIT3 and SPARCL1 protein and the recurrence of cervical cancer after radical operation. Methods From October 2019 to April 2021， 107 patients who underwent radical surgery for cervical cancer in the hospital were selected as the study subjects， and 30 patients with benign uterine lesions were selected as the control group； The patients were followed up for 1 year and were divided into relapse group （n = 25） and non relapse group （n = 82） according to the follow-up results. The expression levels of SLIT3 and SPARCL1 mRNA were detected by real-time fluorescence quantitative analysis （qPCR），and the expression levels of SLIT3 and SPARCL1 protein were detected by immunohistochemistry. The correlation between the expression of SLIT3 and SPARCL1 protein and clinicopathological characteristics was analyzed. Cox model was used to analyze the risk factors of cervical cancer recurrence after radical operation. Results The expression of SLIT3 and SPARCL1 mRNA in cervical cancer group was significantly lower than that in control group （P < 0.05）；The levels of SLIT3 and SPARCL1 mRNA in cervical cancer tissues of patients with recurrence were significantly lower than those of patients without recurrence （P < 0.05）.Among 107 patients with radical operation， 25 patients recurred， the recurrence rate was 23.36%. The postoperative recurrence rate of patients with low expression of SLIT3（31.15%） was significantly higher than that of patients with high expression of SLIT3（13.04%）. The postoperative recurrence rate of patients with low expression of SPARCL1（32.31%） was significantly higher than that of patients with high expression of sparcl1（9.52%）. The difference was statistically significant （P < 0.05）. The expression of SLIT3 and SPARCL1 in cervical cancer was correlated with the degree of differentiation， clinical stage， lymph node metastasis and depth of stromal invasion （P < 0.05）， but not with age， pathological type and maximum diameter of tumor （P > 0.05）.Cox univariate analysis showed that the degree of differentiation， clinical stage， lymph node metastasis， stromal invasion depth， SLIT3 protein expression and SPARCL1 protein expression were correlated with the recurrence of cervical cancer patients after radical surgery （P < 0.05）；Cox multivariate analysis showed that moderate/high differentiation， stage IIA， lymph node metastasis， stromal invasion depth > 50%， low expression of SLIT3 protein and SPARCL1 protein were independent risk factors for recurrence of cervical cancer patients after radical surgery （P < 0.05）. Conclusion the expression of SLIT3 and SPARCL1 in cervical cancer tissue is lower than that in normal cervical tissue. The low expression of SLIT3 and SPARCL1 protein is an independent risk factor for the recurrence of cervical cancer after radical operation， and has certain clinical significance in predicting the recurrence of cervical cancer after operation.